CLINICAL REVIEW: A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 7, 2005, Pages 4405-4410

  Melmed, Shlomo ^a,i   Sternberg, Richard ^b   Cook, David ^c   Klibanski, Anne ^d   Chanson, Philippe ^e   Bonert, Vivien ^a   Vance, Mary Lee ^f   Rhew, David ^b   Kleinberg, David ^g   Barkan, Ariel ^h  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Zynx Health   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e BICÊTRE HOSPITAL   (France)

^f UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^g NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^h UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

ⁱ CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; OCTREOTIDE; SOMATOSTATIN DERIVATIVE; DOPAMINE RECEPTOR STIMULATING AGENT; DRUG DERIVATIVE; SOMATOMEDIN C; SOMATOSTATIN;

ACROMEGALY; CLINICAL PROTOCOL; HUMAN; HYPOPHYSIS TUMOR; PATIENT CARE; PRIORITY JOURNAL; REVIEW; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; TUMOR VOLUME; ARTICLE; CLINICAL TRIAL; PATHOLOGY;

ACROMEGALY; CLINICAL TRIALS; DOPAMINE AGONISTS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; PITUITARY NEOPLASMS; SOMATOSTATIN;

EID: 23044466974     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2004-2466     Document Type: Review

References (35)

1. Abe T, Ludecke DK 2001 Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre. Eur J Endocrinol 145:137-145
2. Amato G, Mazziotti G, Rotondi M, Iorio S, Doga M, Sorvillo F, Manganella G, Di Salle F, Giustina A, Carella C 2002 Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin Endocrinol (Oxf) 56:65-71
3. Attanasio R, Baldelli R, Pivonello R, Grottoli S, Bocca L, Gasco V, Giusti M, Tamburrano G, Colao O, Cozzi R 2003 Lanreotide 60 mg, a new long-acting formulation: effectiveness in the chronic treatment of acromegaly. J Clin Endocrinol Metab 88:5258-5265
4. Baldelli R Colao A, Razzore P, Jaffrain-Rea ML, Marzullo P, Ciccarelli E, Ferretti E, Ferone D, Gaia D, Camanni F, Lombardi G, Tamburrano G 2000 Two-year follow-up of acromegalic patients treated with slow release Lanreotide (30 mg). J Clin Endocrinol Metab 85:4099-4103
5. Bevan J, Atkin S, Atkinson AB, Bouloux PM, Hanna F, Harris PE, James RA, McConnell M, Roberts GA, Scanlon MF, Stewart PM, Teasdale E, Turner HE, Wass JA, Wardlaw JM 2002 Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab 87:4554-4563
6. Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, Lancranjan I, Lombardi G 2001 Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 86:2779-2786
7. Colao A, Ferone D, Cappabianca P, del Basso De Caro ML, Marzullo P, Monticelli A, Alfieri A, Merola B, Cali A, de Divitiis E, Lombardi G 1997 Effect of octreotide pretreatment on surgical outcome in acromegaly. J Clin Endocrinol Metab 82:3308-3314
8. Kristof R, Stoffel-Wagner B, Klingmuller D, Schramm J 1999 Does octreotide treatment improve the surgical results of macro-adenomas in acromegaly? A randomized study. Acta Neurochir 141:399-405
9. Lucas T, Astorga R, Catala M, Spanish Multicenter Lanreotide Study Group on Acromegaly 2003 Preoperative Lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage. Clin Endocrinol (Oxf) 58:471-481
10. Lundin P, Engstrom B, Karlsson F, Burman P 1997 Long-term octreotide therapy in growth hormone-secreting pituitary adenomas: evaluation with serial MR. AJNR Am J Neuroradiol 18:765-772
11. Newman C, Melmed S, George A, Torigian D, Duhaney M, Snyder P, Young W, Klibanski A, Molitch ME, Gagel R, Sheeler L, Cook D, Malarkey W, Jackson I, Vance ML, Barkan A, Frohman L, Kleinberg DL 1998 Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab 83:3034-3040
12. Plockinger U, Reichel M, Fett U, Saeger W, Quabbe H 1994 Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy. J Clin Endocrinol Metab 79:1416-1423
13. Stevenaert A, Beckers A 1996 Presurgical octreotide: treatment in acromegaly. Metabolism 45(Suppl 1):72-74
14. Tachibana E, Saito K, Yoshida J 1999 Preoperative short-term administration of octreotide for facilitating transsphenoidal removal of invasive growth hormone-secreting macroadenomas. Neurol Med Chir 39:496-501
15. Tamura M, Yokoyama N, Abe Y, Sera N, Tominaga T, Ashizawa K, Ejima E, Kiriyama T, Uetani M, Kuwayama A, Nagataki S 1998 Preoperative treatment of growth hormone-producing pituitary adenoma with continuous subcutaneous infusion of octreotide. Endocr J 45:269-275
16. Abs R, Verhelst J, Maiter D, Van Acker K, Nobels F, Coolens JL, Mahler C, Beckers A 1998 Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab 83:374-378
17. Cozzi R, Attanasio R, Barausse M, Dallabonzana D, Orlandi P, Da Re N, Branca V, Oppizzi G, Gelli D 1998 Cabergoline in acromegaly: a renewed role for dopamine agonist treatment? Eur J Endocrinol 139:516-521
18. Halse J, Harris AG, Kvistborg A, Kjartansson O, Hanssen E, Smiseth O, Djosland O, Haas G, Jervell J 1990 A randomized study of SMS 201-995 versus bromocriptine treatment in acromegaly: clinical and biochemical effects. J Clin Endocrinol Metab 70:1254-1261
19. Plockinger U, Quabbe HJ 1991 Evaluation of a repeatable depot-bromocriptine preparation (Parlodel LAR) for the treatment of acromegaly. J Endocrinol Invest 14:943-948
20. Sachdev Y, Gomez-Pan A, Tunbridge WM 1975 Bromocriptine therapy in acromegaly. Lancet 2:1164-1168
21. Oppizzi G, Liuzzi A, Chiodini P, Dallabonzana D, Spelta B, Silvestrini F, Borghi G, Tonon C 1984 Dopaminergic treatment of acromegaly: different effects on hormone secretion and tumor size. J Clin Endocrinol Metab 58:988-992
22. Colao A, Ferone D, Marzullo P, DiSarno A, Cerbone G, Sarnacchiaro F, Cirillo S, Merola B, Lombardi G 1997 Effect of different dopaminergic agents in the treatment of acromegaly. J Clin Endocrinol Metab 82:518-523
23. Freda PU 2002 Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 87:3013-3018
24. Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ 1996 Octreotide. N Engl J Med 25:246-254
25. Hofland LJ, Lamberts SW 2003 The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 24:28-47
26. Ben-Shlomo A, Melmed S 2003 Clinical review 154: the role of pharmacotherapy in perioperative management of patients with acromegaly. J Clin Endocrinol Metab 88:963-968
27. Ezzat S, Snyder PJ, Young WF, Boyajy LD, Newman C, Klibanski A, Molitch ME, Boyd AE, Sheeler L, Cook DM1992 Octreotide treatment of acromegaly. A randomized, multicenter study. Ann Intern Med 117:711-718
28. Melmed S, Casanueva FF, Cavagnini F, Chanson P, Frohman L, Grossman A, Ho, Kleinberg D, Lamberts S, Laws E, Lombardi G, Vance ML, Werder KV, Wass J, Giustina A 2002 Acromegaly treatment consensus workshop participants. Guidelines for acromegaly management. J Clin Endocrinol Metab 87:4054-4058
29. Clemmons DR, Chihara K, Freda PU, Ho KK, Klibanski A, Melmed S, Shalet SM, Strasburger CJ, Trainer PJ, Thorner MO 2003 Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm. J Clin Endocrinol Metab 88:4759-4767
30. Giustina A, Boni E, Romanelli G, Grassi V, Giustina G 1995 Cardiopulmonary performance during exercise in acromegaly, and the effects of acute suppression of growth hormone hypersecretion with octreotide. Am J Cardiol 75:1042-1047
31. Barker II FG, Klibanski A, Swearingen B 2003 Transsphenoidal surgery for pituitary tumors in the United States, 1996-2000: mortality, morbidity, and the effects of hospital and surgeon volume. J Clin Endocrinol Metab 88:4709-4719
32. Laws ER, Sheehan JP, Sheehan JM, Jagnathan J, Jane Jr JA, Oskouian R 2004 Stereotactic radiosurgery for pituitary adenomas: a review of the literature. J Neurooncol 69:257-272
33. Van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friedn KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LA, Strasburger CJ, Hackett S, Zib KA, Davis RJ, Scarlett JA, Thorner MO 2001 Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358:1754-1759
34. Holdaway IM, Rajasoorya RC, Gamble GD 2004 Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89:667-674
35. Ayuk J, Clayton RN, Holder G, Shepphard MC, Stewart PM, Bates AS 2004 Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 89:1613-1617